THE Neuromodulation Society of Australia and New Zealand (NSANZ) has raised the alarm over the Australian Government's new Private Health Insurance (PHI) policy changes, saying they may affect Australians with chronic pain.
Under the new arrangement, which takes effect 01 Apr 2019, unless a patient has a top-tier "Gold" health policy, they may be unable to access device-based pain management treatments.
The NSANZ, which brings together experts in the alteration of nerve activity through the delivery of electromagnetic stimulation or chemical agents, says the change may force drug-based solutions and worsen the opioid crisis.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Oct 18
